Shares of Israel-based Enlivex Therapeutics Ltd. (ENLV) rocketed 53% in active premarket trading Monday, after the clinical-stage immunotherapy company said it has started a plan to increase its manufacturing capacity of Allocetra, following the first confirmed case of COVID-19 in Israel. Trading volume rose to about 76,000 shares, compared with the full-day average of about 17,000 shares. Allocetra is being studied for the treat of patients with organ failure associated with sepsis, which the company said the lethal pathophysiology, which is cytokine storm followed by organ failure, is similar to that of COVID-19. The stock has run up 19.6% over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF (IBB) has gained 6.7% and the S&P 500 has advanced 7.3%.
-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
February 24, 2020 08:18 ET (13:18 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.